⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Nanopharm and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Nanopharm
↗Newport, Wales, United Kingdom
Nanopharm is a leading Contract Research Organization (CRO) specializing in the design and development of Orally Inhaled and Nasal Drug Products (OINDPs). The company provides comprehensive services including formulation development, analytical testing, and regulatory support, utilizing proprietary in vitro and in silico modeling platforms to accelerate drug development and de-risk the regulatory pathway for both branded and generic products.
Since its acquisition by AptarGroup in 2019, Nanopharm has operated as a key subsidiary within the Aptar Pharma Services platform. The company is renowned for its scientific expertise in aerosol-based drug delivery and its ability to support clients from discovery through to clinical investigations and market launch.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$10M-$15M
Founded:2002
Ownership:subsidiary
Status:operating
STOCK
Exchange:NYSE
Ticker:ATR
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Service Provider)
Modalities:Inhaled, Nasal, Biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:AptarGroup
Acquired By:AptarGroup (2019-06-01)
Key Partnerships:Fluidda (Exclusive collaboration for Functional Respiratory Imaging and SmartTrack platform)
COMPETITION
Position:Leader
Competitors:Jubilant Life Sciences, Akums, Nivagen Pharmaceuticals, Curida
LEADERSHIP
Key Executives:
Gemma Budd - General Manager
Dr. Robert Price - Co-Founder
Dr. Jag Shur - Co-Founder / VP Science & Technology
Scientific Founders:Dr. Robert Price, Dr. Jag Shur
LINKS
Website:nanopharm.co.uk
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nanopharm. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.